WSE:AWM

Stock Analysis Report

Executive Summary

Airway Medix S.A. engages in the research, development, and commercialization of disposable devices for the mechanically ventilated patients in the intensive care units and for the patients in life-threatening conditions in the anaesthesiology departments.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Airway Medix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.8%

AWM

1.8%

PL Medical Equipment

1.5%

PL Market


1 Year Return

-10.4%

AWM

-14.1%

PL Medical Equipment

-3.1%

PL Market

Return vs Industry: AWM exceeded the Polish Medical Equipment industry which returned -14.1% over the past year.

Return vs Market: AWM underperformed the Polish Market which returned -3.1% over the past year.


Share holder returns

AWMIndustryMarket
7 Day6.8%1.8%1.5%
30 Day3.3%-4.2%-2.1%
90 Day1.5%-6.6%-7.7%
1 Year-10.4%-10.4%-14.1%-14.1%-0.2%-3.1%
3 Year-61.5%-61.5%-79.4%-79.6%12.0%4.0%
5 Yearn/a-77.1%-80.8%0.2%-11.9%

Price Volatility Vs. Market

How volatile is Airway Medix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Airway Medix undervalued based on future cash flows and its price relative to the stock market?

1.21x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate AWM's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate AWM's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: AWM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AWM is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate AWM's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: AWM is overvalued based on its PB Ratio (1.2x) compared to the PL Medical Equipment industry average (0.8x).


Next Steps

Future Growth

How is Airway Medix expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Airway Medix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Airway Medix performed over the past 5 years?

10.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AWM is unprofitable, but has reduced losses over the past 5 years at a rate of 10.1% per year.

Accelerating Growth: Unable to compare AWM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AWM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (4.3%).


Return on Equity

High ROE: AWM has a negative Return on Equity (-5.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AWM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AWM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Airway Medix's financial position?


Financial Position Analysis

Short Term Liabilities: AWM's short term assets (PLN8.2M) exceeds its short term liabilities (PLN1.9M)

Long Term Liabilities: AWM's short term assets (PLN8.2M) exceeds its long term liabilities (PLN7.1M)


Debt to Equity History and Analysis

Debt Level: AWM is debt free.

Reducing Debt: AWM had no debt 5 years ago.


Balance Sheet

Inventory Level: AWM has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AWM's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AWM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AWM has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.5% each year.


Next Steps

Dividend

What is Airway Medix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.6%markettop25%7.3%industryaverage1.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate AWM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AWM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AWM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AWM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AWM's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

What is the CEO of Airway Medix's salary, the management and board of directors tenure and is there insider trading?

zł177k

CEO Compensation


CEO

Marek Orlowski (50yo)

0yrs

Tenure

zł177,000

Compensation

Mr. Marek Jan Orlowski, M.D., serves as General Partner of Joint Polish Investment Fund C.V. Mr. Orlowski serves as a General Partner at Joint Polish Investment Fund Management B.V. He serves as the Presid ...


CEO Compensation Analysis

Compensation vs. Market: Marek's total compensation ($USD45.50K) is too low to compare against companies of similar size in the Polish market ($USD0.00).

Compensation vs Earnings: Marek's compensation has increased whilst the company is unprofitable.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Marek Orlowski (50yo)

    President of Management Board

    • Tenure: 0yrs
    • Compensation: zł177.00k
  • Anna Aranowska-Bablok

    Member of Management Board

    • Tenure: 0yrs
    • Compensation: zł141.00k
  • Oron Zachar

    Member of Management Board

    • Tenure: 0yrs

Board Members

  • Pawel Nauman

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł1.20k
  • Tomasz Poninski

    Chairman of Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł6.00k
  • Maria Gajda

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł1.20k
  • Dariusz Zimny

    Member of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł2.40k
  • Krzysztof Laskowski

    Member of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł6.00k

Company Information

Airway Medix S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Airway Medix S.A.
  • Ticker: AWM
  • Exchange: WSE
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: zł40.309m
  • Shares outstanding: 58.42m
  • Website: https://www.airwaymedix.pl

Location

  • Airway Medix S.A.
  • ul. Slominskiego 15 lok 509
  • Warsaw
  • 00-195
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AWMWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNDec 2014

Biography

Airway Medix S.A. engages in the research, development, and commercialization of disposable devices for the mechanically ventilated patients in the intensive care units and for the patients in life-threate ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 23:37
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)